STAAR SURGICAL CO (STAA) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does STAAR SURGICAL CO Do?
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California. STAAR SURGICAL CO (STAA) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Caren L. Mason and employs approximately 960 people, headquartered in MONROVIA, California. With a market capitalization of $886M, STAA is one of the notable companies in the Healthcare sector.
STAAR SURGICAL CO (STAA) Stock Rating — Reduce (April 2026)
As of April 2026, STAAR SURGICAL CO receives a Reduce rating with a composite score of 41.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.STAA ranks #2,630 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, STAAR SURGICAL CO ranks #307 of 839 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
STAA Stock Price and 52-Week Range
STAAR SURGICAL CO (STAA) currently trades at $20.21. The 52-week high for STAA is $30.81, which means the stock is currently trading -34.4% from its annual peak. The 52-week low is $14.69, putting the stock 37.6% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is STAA Overvalued or Undervalued? — Valuation Analysis
STAAR SURGICAL CO (STAA) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 102.17x, compared to the Healthcare sector average of 23.29x — a premium of 339%. The price-to-book ratio stands at 2.78x, versus the sector average of 2.69x. The price-to-sales ratio is 3.54x, compared to 1.64x for the average Healthcare stock. On an enterprise value basis, STAA trades at 11.82x EV/EBITDA, versus 6.36x for the sector.
At current multiples, STAAR SURGICAL CO trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.
STAAR SURGICAL CO Profitability — ROE, Margins, and Quality Score
STAAR SURGICAL CO (STAA) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is -15.2%, compared to the Healthcare sector average of -42.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.6% versus the sector average of -33.1%.
On a margin basis, STAAR SURGICAL CO reports gross margins of 74.8%, compared to 71.3% for the sector. The operating margin is -44.1% (sector: -65.2%). Net profit margin stands at -36.1%, versus -54.1% for the average Healthcare stock. Revenue growth is running at -4.3% on a trailing basis, compared to 10.7% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
STAA Debt, Balance Sheet, and Financial Health
STAAR SURGICAL CO has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 31.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.55x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $176M.
STAA has a beta of 0.66, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for STAAR SURGICAL CO is 48/100, reflecting average volatility within the normal range for its sector.
STAAR SURGICAL CO Revenue and Earnings History — Quarterly Trend
In TTM 2026, STAAR SURGICAL CO reported revenue of $270M and earnings per share (EPS) of $-1.62. Net income for the quarter was $-52M. Gross margin was 74.8%. Operating income came in at $-63M.
In FY 2025, STAAR SURGICAL CO reported revenue of $239M and earnings per share (EPS) of $-1.62. Net income for the quarter was $-80M. Gross margin was 76.2%. Revenue grew -23.7% year-over-year compared to FY 2024. Operating income came in at $-92M.
In Q3 2025, STAAR SURGICAL CO reported revenue of $95M and earnings per share (EPS) of $0.18. Net income for the quarter was $9M. Gross margin was 82.2%. Revenue grew 6.9% year-over-year compared to Q3 2024. Operating income came in at $18M.
In Q2 2025, STAAR SURGICAL CO reported revenue of $44M and earnings per share (EPS) of $-0.34. Net income for the quarter was $-17M. Gross margin was 74.0%. Revenue grew -55.2% year-over-year compared to Q2 2024. Operating income came in at $-30M.
Over the past 8 quarters, STAAR SURGICAL CO has demonstrated a growth trajectory, with revenue expanding from $99M to $270M. Investors analyzing STAA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
STAA Dividend Yield and Income Analysis
STAAR SURGICAL CO (STAA) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
STAA Momentum and Technical Analysis Profile
STAAR SURGICAL CO (STAA) has a momentum factor score of 34/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.
STAA vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, STAAR SURGICAL CO (STAA) ranks #307 out of 839 stocks based on the Blank Capital composite score. This places STAA in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.5/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.3/100, HOLOGIC INC (HOLX) with a score of 52.8/100, FONAR CORP (FONR) with a score of 53.0/100, and Royalty Pharma plc (RPRX) with a score of 53.4/100.
Comparing STAA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STAA vs S&P 500 (SPY) comparison to assess how STAAR SURGICAL CO stacks up against the broader market across all factor dimensions.
STAA Next Earnings Date
No upcoming earnings date has been announced for STAAR SURGICAL CO (STAA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy STAA? — Investment Thesis Summary
The quantitative profile for STAAR SURGICAL CO suggests caution. The value score of 23/100 indicates premium valuation. Momentum is weak at 34/100, a headwind for near-term performance.
In summary, STAAR SURGICAL CO (STAA) earns a Reduce rating with a composite score of 41.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STAA stock.
Related Resources for STAA Investors
Explore more research and tools: STAA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STAA head-to-head with peers: STAA vs AZN, STAA vs SLGL, STAA vs HOLX.